NEXGEL, Inc. (NASDAQ:NXGL) CEO Sells $14,560.00 in Stock

NEXGEL, Inc. (NASDAQ:NXGL) CEO Adam R. Levy sold 4,000 shares of the firm’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $3.64, for a total value of $14,560.00. Following the transaction, the chief executive officer now owns 378,284 shares in the company, valued at approximately $1,376,953.76. The trade was a 1.05 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

NEXGEL Stock Performance

Shares of NXGL stock opened at $3.31 on Friday. The company has a market capitalization of $22.47 million, a P/E ratio of -5.71 and a beta of 0.57. NEXGEL, Inc. has a fifty-two week low of $1.84 and a fifty-two week high of $5.10. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.93 and a current ratio of 1.51. The stock has a 50 day moving average price of $3.86 and a two-hundred day moving average price of $3.20.

Institutional Investors Weigh In On NEXGEL

A hedge fund recently raised its stake in NEXGEL stock. Northeast Financial Group Inc. raised its position in NEXGEL, Inc. (NASDAQ:NXGL) by 168.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 31,848 shares of the company’s stock after acquiring an additional 20,000 shares during the quarter. Northeast Financial Group Inc. owned approximately 0.50% of NEXGEL worth $82,000 at the end of the most recent quarter. 2.21% of the stock is owned by institutional investors and hedge funds.

About NEXGEL

NEXGEL, Inc manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc and changed its name to NEXGEL, Inc in November 2019.